Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

Similar articles for PubMed (Select 23775094)

1.

Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.

Sicklick JK, Lopez NE.

J Gastrointest Surg. 2013 Nov;17(11):1997-2006. doi: 10.1007/s11605-013-2243-0. Epub 2013 Jun 18. Review.

2.

NCCN Task Force report: gastrointestinal stromal tumor (GIST).

Demetri G, DeMatteo RP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 3:S-25-8. No abstract available.

PMID:
23570095
3.

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID:
17072676
4.

New fronts in the adjuvant treatment of GIST.

Reichardt P, Joensuu H, Blay JY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):715-23. doi: 10.1007/s00280-013-2248-0. Epub 2013 Aug 11. Review.

PMID:
23934322
5.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.

Eur J Cancer. 2014 Jul;50(10):1772-8. doi: 10.1016/j.ejca.2014.03.280. Epub 2014 Apr 22.

PMID:
24768330
6.
7.

Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.

Pandey R, Kochar R.

J Gastrointest Cancer. 2012 Dec;43(4):547-52. doi: 10.1007/s12029-012-9423-0. Review.

PMID:
22847491
8.

[Treatment progress of gastrointestinal stromal tumor].

Ji X, Ji JF.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):292-6. Review. Chinese.

PMID:
23536354
9.

Modern treatment of gastric gastrointestinal stromal tumors.

Roggin KK, Posner MC.

World J Gastroenterol. 2012 Dec 14;18(46):6720-8. doi: 10.3748/wjg.v18.i46.6720.

10.

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Shen C, Chen H, Yin Y, Chen J, Zhang B, Chen Z, Chen J.

Clinics (Sao Paulo). 2014 Nov;69(11):758-62. doi: 10.6061/clinics/2014(11)09.

11.

Metastasectomy for gastrointestinal stromal tumors.

Bamboat ZM, DeMatteo RP.

J Surg Oncol. 2014 Jan;109(1):23-7. doi: 10.1002/jso.23451. Epub 2013 Oct 24. Review.

12.

Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.

Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P.

Ann Surg Oncol. 2013 Feb;20(2):586-92. doi: 10.1245/s10434-012-2647-1. Epub 2012 Sep 11.

PMID:
22965573
13.

Practical aspects of risk assessment in gastrointestinal stromal tumors.

Jones RL.

J Gastrointest Cancer. 2014 Sep;45(3):262-7. doi: 10.1007/s12029-014-9615-x. Review.

14.

Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).

Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A.

Eur J Surg Oncol. 2014 Apr;40(4):412-9. doi: 10.1016/j.ejso.2013.12.020. Epub 2014 Jan 15.

PMID:
24491288
15.

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours.

Iorio N, Sawaya RA, Friedenberg FK.

Aliment Pharmacol Ther. 2014 Jun;39(12):1376-86. doi: 10.1111/apt.12761. Epub 2014 Apr 20. Review.

PMID:
24749828
16.

Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.

Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP.

Eur J Surg Oncol. 2014 Apr;40(4):420-8. doi: 10.1016/j.ejso.2013.10.021. Epub 2013 Nov 5.

PMID:
24238762
17.

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.

Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG.

BMC Gastroenterol. 2014 Jun 7;14:105. doi: 10.1186/1471-230X-14-105.

18.

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczyk M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F.

Ann Surg Oncol. 2013 Sep;20(9):2937-43. doi: 10.1245/s10434-013-3013-7. Epub 2013 Jun 13.

PMID:
23760587
19.

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.

Anticancer Drugs. 2008 Jul;19(6):607-12. doi: 10.1097/CAD.0b013e32830138f9.

PMID:
18525320
20.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Epub 2011 Dec 28. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk